AKBAMAX ®Containing Boswellic Acids ! ! ! !
Alpha boswellic acid 3 acetyl alpha and beta boswellic acid 11 keto beta boswellic acid 3 acetyl 11 keto beta boswellic acid (AKBA)
Most Potent Boswellic acid Having Anti-inflammatory Properties.
AKBA
AKBAMAX
KBA
ABA
BA
standardized with 10% AKBA
AKBAMAX ( Bospure in USA) • • • • • • •
Standardized with 10% AKBA Enriched with acetyl group of boswellic acids Does not contain beta boswellic acids Total boswellic acids minimum 40% (HPLC) Does not use strong acids for acetylation Natural inhibitor of leukotrienes (LOX) Clinically proven to be potent anti inflammatory and anti-arthritic
AKBAMAX - Therapy For Inflammation Arachidonic acid 20:4 w6
Cyclooxygenase –2 (COX-2)
5-Lipoxygenase
COX-2 inhibitors do not block 5-lipoxygenase pathway Prostaglandin E2 (PGE-2)
Leukotriene B (4)
Inflammation, pain and joint destruction
AKBA Inhibits
AKBAMAX Indications For Use Advantages • Unique LOX inhibition • Safety profile: high • Traditionally advocated
Indications for use • Muscle pain • Cramps • Tendon injury • Swollen and tender joints • Arthritis • Chronic pain • Elderly subjects • Add on drug
AKBAMAX How Is It Different? Boswellic acids (HPLC) Contains AKBA Acetyl boswellic acids Major component
65% BA
75%-85% BA
AKBAMAX
20% - 25%
40% - 45%
40% - 45%
6 BAs
6 BAs
3 BAs
1% - 2%
2% - 3%
Min 10%
1,5% - 3%
2% -4%
4% - 6%
β -BA
β -BA
ABA (β -BA absent)
β-boswellic acid stimulates the platelet-induced generation of thrombin, liberation of arachidonic acid and induces platelet aggregation. In contrast AKBA or KBA did not cause aggregation or generation of thrombin. Ref: Poeckel D, Tausch L, Altmann K, et al. Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid, Br. J. Pharmacol., 2005, 146:514-26
AKBA 3% - 10% - 30% Which is better?
Study of lipoxygenase inhibitory effect – In vitro study in human monocytes • 5-LOX and 15-LOX inhibited in a dose dependent manner • 3% vs 10%: significant inhibition • 10% vs 30%: no further significant inhibition
Is there any REAL competitor?
Which Wo hin cheonies s the m the im poteonst ost p o t e n t? t?
Is there any REAL competitor? Casperom e >25%
triterpenoids acids Phytosome technology
Boswellia extract
65% boswellic acids (generics)
Boswellin 65% boswellic acids
Boswellin ® PS
10% AKBA 20% total boswellic acids 35% total organic acids
AKBAMAX ® 10% AKBA acetyl group of BA no β-BA
BSE (Cepham inc) 10% AKBA 75% total boswellic acids 40% beta boswellic acids
WokVel
65% organic acids 40% total BA
5-LOXIN 30% AKBA
Aflapin® 20% AKBA
AKBAMAX On Osteoarthritis - HCT
Clinical evaluation of a herbal formulation, Rhulief in the management of osteoarthritis Molecular Medicine Reports, 2013
AKBAMAX On Osteoarthritis HCT
Clinical evaluation of a herbal formulation, Rhulief in the management of osteoarthritis – Molecular Medicine Reports, 2013
! Rhulief highly effective as NSAID in OA ! Symptomatic and functional improvement with Rhulief in OA
AKBAMAX Toxicity Study •
Acute Oral Toxicity Study in wistar rats and swiss albino mice – No adverse effects observed • No Observed Effect Level : 2000 mg/kg • LD50 > 2000mg/kg
• •
28 day repeat dose oral toxicity study – No adverse effects observed No Observed Adverse Effect Level – 500mg/kg
•
Mutagenicity Studies - did not induce any mutagenic effect.
•
Reproduction Toxicity Segment 1 - did not elicit any observable toxic effects on reproductive performance of the animals No Observed Adverse Effect Level – 500mg/kg
• • •
90 days repeated dose oral toxicity study - No significant difference between the treatment and control group. No Observed Effect Level : > 500 mg/kg b.wt. – Ref: A 90 day gavage safety assessment of Boswellia serrata in rats, Toxicology International Sep-Dec 2012 / Vol-19 / Issue-13
BCM-95 + AKBAMAX as a strong antiinflammatory team
SAFETY PROVEN AT HIGH DOSAGE AND LONG TERM